ライフサイエンスコーパス: MDR

1 MDR and XDR tuberculosis are associated with high morbid

2 MDR and XDR-TB isolates were significantly more likely t

3 MDR is typically associated with transmembrane proteins

4 MDR(+) cells were frequently observed in leukemic blast

5 MDR-TB was defined as culture-confirmed TB disease with

6 ulation per year (95% SI: 198, 269) with 14% MDR-TB.

7 103 (32%) of the 324 MDR strains were in 38 genomic clusters that differed by

8 Geneticists rated PCP management of 8 MDR results (73% [CI, 39% to 99%]) as appropriate and 2

9 , 9 (53%) inpatients had colonization with a MDR bacterium that was not identified by culture.

10 into leukemic blast cells with MDR activity (MDR(+)) and leukemic blast cells without MDR activity (M

11 d leukemic blast cells without MDR activity (MDR(-ve)).

12 ls, their spectra of activity do not address MDR pathogens such as Acinetobacter baumannii.

13 Furthermore, the strategy that co-administer MDR-ABCB1 inhibitor to overcome the resistance of one FD

14 tics with improved in vitro activity against MDR pathogens using recently updated guidelines for acti

15 the hybrid possesses potent activity against MDR, P. aeruginosa isolates the activity that can be syn

16 bacterial activity, in vivo efficacy against MDR A. baumannii infections and promising preclinical sa

17 rkably improved therapeutic efficacy against MDR tumors with minimal side effects.

18 ations, the test can detect about 60% of all MDR-TB cases.

19 Although providing bedaquiline to all MDR patients resulted in the highest life expectancy for

20 oquinolones have high resistance rates among MDR uropathogens and are being strongly discouraged as f

21 baumannii with the MBC of 2.0 mug/mL and an MDR A. baumannii with the MBC of 3.13 mug/mL.

22 d evidence of the phenotypes predicted by an MDR result (fundus albipunctatus due to RDH5 and variega

23 for the incidence density of candidemia and MDR BSI (+0.018 cases per 1000 OBDs per quarter; 95% con

24 ity rate of hospital-acquired candidemia and MDR BSI through sustained reduction in antibiotic use.

25 mase (ESBL)-producing Enterobacteriaceae and MDR Acinetobacter baumannii.

26 The high prevalence of MRSA and MDR bacterial pathogens dictate the need for effective p

27 tal infection control practices for MRSA and MDR-AB (ie, contact precautions, private room/cohorting,

28 Although fundamental MRSA and MDR-AB control practices are used regularly in most Thai

29 d replication of clinically-isolated MTB and MDR-TB strains.

30 In the new smear-negative and MDR TB cascades, a substantial proportion of patients wh

31 e of care, especially for smear-negative and MDR TB patients.

32 b IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable ph

33 Retreatment smear-positive and MDR TB patients had poorer treatment outcomes than the g

34 D as a new and effective drug against TB and MDR-TB.

35 ual per-capita incidence of tuberculosis and MDR-tuberculosis by HC, with a rate of MDR-tuberculosis

36 improve patients' health, protect background MDR TB drugs, and decrease transmission, but would likel

37 multidrug-resistant gram-negative bacteria (MDR-GNB) in adult intensive care units (ICUs).

38 multidrug-resistant Acinetobacter baumannii (MDR-AB) were assessed.

39 that capsular switching has occurred between MDR vaccine serotypes belonging to ST156 (e.g., 9V, 14,

40 ia coli sequence type (ST) 131, harbors both MDR and a deadly complement of virulence factors.

41 approaches in treating infections caused by MDR bacteria will be heavily influenced by a precision m

42 Deep SSIs, including those caused by MDR bacteria, were common after LTx despite prophylaxis

43 phage therapy for acute pneumonia caused by MDR Pseudomonas aeruginosa in a mouse model.

44 2010 represented excess mortality caused by MDR.

45 ple therapeutic agents, but also help bypass MDR pathways, which are conducive for the efficient deli

46 31 (TCG/TTG) and katG 315 (AGC/ACC)] causing MDR-TB and verification of loss of the respective wild t

47 of common carbapenemase genes using a Check-MDR CT101 microarray (Check-Points, Wageningen, the Neth

48 Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in recurrent gli

49 polymerization and effectively circumvented MDR.

50 in clinical trials in hope of circumventing MDR, with only limited success.

51 ) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in child

52 68 (66%) of 103 clustered MDR strains had compensatory mutations of rifampicin res

53 require KatG activation is crucial to combat MDR TB.

54 wever, we found that pyrazinamide-containing MDR-LTBI regimens often resulted in treatment discontinu

55 ood circulation and effectively downregulate MDR gene expression in vivo to enhance chemotherapeutic

56 tallopeptidases, multidrug-resistant efflux (MDR) pumps, TonB-dependent receptors and many proteins o

57 The estimated MDR-TB incidence reduction was 90% (9%-99%) using data f

58 a serotype Reading isolates were extensively MDR, suggesting a strong association between serotype an

59 Based on the few MDR loci that are well-understood, MDR is conditioned by

60 ity, as well as changing recommendations for MDR TB treatment.

61 Long aggressive regimens for MDR-TB treatment are associated with lower risk of disea

62 sus the least-affected HC; (2) high risk for MDR-tuberculosis in a region spanning several HCs (odds

63 apy where bacteriophages exert selection for MDR bacteria to become increasingly sensitive to traditi

64 obial drugs are in advanced trial stages for MDR tuberculosis, and two new antimicrobial drug candida

65 ents treated with ceftolozane-tazobactam for MDR-P. aeruginosa infections.

66 useful in developing combination therapy for MDR cancer treatment.

67 treated compared with those not treated for MDR-LTBI; 10 presented outcomes only for treated contact

68 s for clinically diagnosed cases treated for MDR-TB.

69 pants (69%) had never received treatment for MDR tuberculosis.

70 uced risk of TB incidence with treatment for MDR-LTBI, suggesting effectiveness in prevention of prog

71 ted great promise as potential treatment for MDR-related tumors based on the synergistic effects of P

72 or MRSA, and hydrogen peroxide vaporizer for MDR-AB) were used less commonly.

73 owever, pronounced variability in functional MDR activity between leukemic blasts was observed, with

74 The risk of generating MDR de novo is highest between 40% and 80% adherence.

75 s having disease recurrence if cultures grew MDR-TB or they re-initiated MDR-TB therapy.

76 h drug susceptibility testing, 82 (1.7%) had MDR-TB.

77 20 adults with AML whose leukemic blasts had MDR activity against the anthracyline daunorubicin (DNR)

78 (5%) of 7982 patients with tuberculosis had MDR tuberculosis and 324 (88%) of these had isolates ava

79 s from patients in India suspected of having MDR-TB.

80 t multiple-case and 88 single-case household MDR strains were analyzed for 10 specific drug resistanc

81 characteristics associated with decreases in MDR-AB rates, greater compliance with the MDR-AB prevent

82 PR2 can be reactivated for genome defense in MDR strains.

83 there remains minimal data on differences in MDR activity at the individual cell level.

84 esistance to first- and second-line drugs in MDR and XDR-TB.

85 e the mechanistic basis for heterogeneity in MDR activity at the individual cell level.

86 hip-based assay to identify heterogeneity in MDR activity in leukemic blasts.

87 h generally through regulatory innovation in MDR tuberculosis.

88 reventive strategies (such as prophylaxis in MDR and XDR contacts), palliative and patient-orientated

89 vention bundle did not lead to reductions in MDR-AB rates.

90 says that can distinguish the variability in MDR activity between individual leukemic blasts are lack

91 ercentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8.9% (95% predict

92 is reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident

93 tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resista

94 stance would cause less than 30% of incident MDR tuberculosis during 2000-40.

95 ia and ionizing radiation was used to induce MDR in HCC cells.

96 if cultures grew MDR-TB or they re-initiated MDR-TB therapy.

97 ohort study of adult patients that initiated MDR-TB treatment with individualized regimens between Se

98 INTERPRETATION: MDR and XDR tuberculosis were forecast to increase in al

99 ugs, these are DS (drug sensitive isolates), MDR (multi-drug resistant isolates) and XDR (extremely d

100 Among all invasive serotype 35B isolates, MDR isolates increased significantly, from 2.9% (1/35) t

101 osis incidence in persons treated for latent MDR -TB infection is unknown.

102 At the organismal level, MDR may be controlled by clusters of R genes that evolve

103 sette (ABC) transporters is one of the major MDR mechanisms.

104 ated the appropriateness of how PCPs managed MDR results.

105 TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [(3)H]-paclitaxel

106 peptidomimetic, could reverse ABCB1-mediated MDR in vitro and in vivo.

107 bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transp

108 ry effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation.

109 ese analogues as modulators of P-gp mediated MDR in cancer cells.

110 uctural basis and mechanism of P-gp-mediated MDR.

111 ine daunorubicin (DNR) tested using multiple MDR inhibitors.

112 patients (22% [95% CI, 12% to 36%]) had new MDR results.

113 Such guidance could make the novel MDR tuberculosis regimen available to most patients whil

114 were detected in 32.14%, 78.5% and 10.7% of MDR isolates, respectively.

115 significant reduction in the acquisition of MDR A. baumannii (RR, 0.28 [95% CI, .18-.43] and 0.48 [9

116 2.33, 4.36); and (3) spatial aggregation of MDR-tuberculosis genotypes, suggesting localized transmi

117 n E. coli reservoirs lyse a diverse array of MDR ST131 clinical isolates.

118 erculosis in countries with a high burden of MDR tuberculosis.

119 ends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and So

120 nitrofurantoin remain high for most cases of MDR Escherichia coli UTIs.

121 (95% SI: 246, 558), with 46% being cases of MDR-TB, while incorporating programmatic management of M

122 pre-MDR-TB to prevent further development of MDR-TB.

123 ve alternatives for molecular diagnostics of MDR- and XDR-TB.

124 mellonella larvae from the lethal effects of MDR P. aeruginosa.

125 etic events contributing to the emergence of MDR serotype 35B are unknown.

126 T within the microbiome and the emergence of MDR super-bugs.

127 lic health threat, but accurate estimates of MDR-TB burden among children are lacking.

128 composition, transmission, and evolution of MDR- and XDR-TB in Belarus and will enable improved diag

129 and the genetic composition and evolution of MDR- and XDR-TB in the region, we sequenced and analyzed

130 ng pathway, leading to reduced expression of MDR transporters and thereby an increased accumulation o

131 approach, we estimated that the majority of MDR-TB was due to the recent transmission of already-res

132 ile incorporating programmatic management of MDR-TB into these programs reduced incidence to 233 case

133 incorporation of programmatic management of MDR-TB is vital if control is to be achieved.

134 lp to determine the transmission patterns of MDR tuberculosis.

135 The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to

136 hospitalization with a similar prevalence of MDR (50% broad spectrum vs. 60% standard).

137 The prevalence of MDR pathogens was 40% in the standard versus 46% in the

138 The increased prevalence of MDR serotype 35B after the introduction of PCV13 was dir

139 The comparative gene expression profile of MDR E. coli 381 and the reference human strain E. coli A

140 of beta-lactam activity in a broad range of MDR Gram-negative pathogens.

141 s and MDR-tuberculosis by HC, with a rate of MDR-tuberculosis 89 times greater (95% confidence interv

142 tance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden

143 ion of FQ-resistant mutations at the time of MDR-TB diagnosis.

144 DR tuberculosis probably had transmission of MDR strains.

145 ms (SNPs), indicating recent transmission of MDR strains.

146 Recent transmission of MDR tuberculosis strains, with increasing drug-resistanc

147 INTERPRETATION: Recent transmission of MDR tuberculosis strains, with increasing drug-resistanc

148 d, they may prove useful in the treatment of MDR GNB infections.

149 ssion rather than to inadequate treatment of MDR tuberculosis.

150 onses and resistance during various types of MDR-P. aeruginosa infections is needed to define ceftolo

151 robial resistance and the emergence of other MDR pathogens, such as malaria, HIV, and Gram-negative b

152 ut decreased the risk of resistance to other MDR drugs.

153 The overall MDR bacterial pathogen proportion was very high.

154 etics, the use of Pgp inhibitors to overcome MDR in the clinical setting remains elusive despite prom

155 al function of nitric oxide (NO) to overcome MDR.

156 ese thiosemicarbazones necessary to overcome MDR.

157 ll discuss the mechanism of NO in overcoming MDR and recent progress of combined NO and drug delivery

158 ly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased t

159 INH-R was found in 86 (26.7%) patients, MDR in 15 (4.7%) patients, rifampicin monoresistance in

160 Most pediatric MDR-TB cases were female (n = 51 [62%]), median age was

161 Better estimates of pediatric MDR-TB burden in the United States are needed and should

162 ere was 42%-55% underestimation of pediatric MDR-TB cases when using only culture-confirmed case defi

163 rtain potential underestimation of pediatric MDR-TB, we surveyed high-burden states for clinically di

164 This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommenda

165 sulting in underestimation of true pediatric MDR-TB burden in the United States using strictly bacter

166 e alone will be insufficient to identify pre-MDR strains.

167 able targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.

168 ving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a

169 s the most effective intervention to prevent MDR-GNB acquisition.

170 genes, and/or by individual genes providing MDR.

171 rated that the various mechanisms regulating MDR in HCC cells are calcium dependent through the TRPC6

172 ave limited access to the new and repurposed MDR-TB drugs.

173 les that confer multiple disease resistance (MDR) are valuable in crop improvement, although the mole

174 ific, providing multiple disease resistance (MDR).

175 s tendency to develop multi-drug resistance (MDR), whose various underlying mechanisms make it diffic

176 arkably rapidly, with multi drug-resistance (MDR) rates exceeding 60%.

177 ncer cells can develop multidrug resistance (MDR) after prolonged exposure to chemotherapeutic drugs,

178 n hospitals, including multidrug resistance (MDR) and its association with serious infectious disease

179 Multidrug resistance (MDR) attenuates the chemotherapy efficacy and increases

180 e of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved th

181 ed in the formation of multidrug resistance (MDR) in cancer chemotherapy.

182 rotein (Pgp) increases multidrug resistance (MDR) in cancer, which greatly impedes satisfactory clini

183 Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapy.

184 Multidrug resistance (MDR) is a major impediment to cancer treatment.

185 gies to overcome tumor multidrug resistance (MDR) is to deliver anticancer drug along with P-glycopro

186 This so-called multidrug resistance (MDR) may be reversed by selective, potent, and nontoxic

187 Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport pr

188 f treatment failure is multidrug resistance (MDR) mediated by the ABCB1, ABCC1, and ABCG2 drug-efflux

189 However, multidrug resistance (MDR) of cancer cells has remained as a significant obsta

190 tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such when treated with antica

191 er, the development of multidrug resistance (MDR) restricts the efficacy of current chemotherapeutic

192 infection was 24% and multidrug resistance (MDR) was observed in 87% of the isolated bacteria.

193 in the development of multidrug resistance (MDR), a major obstacle for successful chemotherapy in ca

194 of the main causes of multidrug resistance (MDR), being capable of effluxing many chemotherapeutics.

195 mpicin monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant multidrug resistance, se

196 creased proliferation, multidrug resistance (MDR), invasion and metastasis.

197 s is a major factor in multidrug resistance (MDR), which makes these pumps important antibacterial dr

198 the expression of 377 multidrug resistance (MDR)-associated genes in two independent cohorts of pati

199 the phenomenon called multidrug resistance (MDR).

200 of the development of multidrug resistance (MDR).

201 ncreased prevalence of multidrug resistance (MDR; 94% compared to 60% in layers), including prevalenc

202 ents to infection with multi-drug resistant (MDR) bacteria are determined by many complex factors.

203 Multi-drug resistant (MDR) enteric bacteria are of increasing global concern.

204 ones effective against multi drug resistant (MDR) Mtb.

205 ased the proportion of multi-drug resistant (MDR) Salmonella from day 4 through day 26, which was the

206 The rise of multi-drug-resistant (MDR) bacteria has spurred renewed interest in the use of

207 nd the epidemiology of multi-drug-resistant (MDR) Escherichia coli (using blaNDM and mcr-1 as marker

208 ded for the analysis of multidrug resistant (MDR) and extensively drug resistant (XDR) Mtb strains th

209 ed drug efflux by model multidrug resistant (MDR) breast cancer cell lines (MCF-7/ADR).

210 oled siRNAs that target multidrug resistant (MDR) genes in the shell.

211 terial activity against multidrug resistant (MDR) Gram-positive and Gram-negative species.

212 ries were predefined as multidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R

213 actam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infections are limited.

214 000 cases of these were multidrug resistant (MDR).

215 se in the proportion of multidrug-resistant (MDR) 35B isolates has recently been reported.

216 Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficul

217 of DR-TB, particularly multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.

218 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis a

219 he increasing burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis.

220 density of Candida and multidrug-resistant (MDR) bacteria bloodstream infections (BSIs) and their cr

221 Multidrug-resistant (MDR) bacterial infections are a serious threat to public

222 ance (AR) and spread of multidrug-resistant (MDR) bacterial pathogens.

223 isoniazid-resistant and multidrug-resistant (MDR) disease than are identified.

224 systems are absent from multidrug-resistant (MDR) Enterococcus faecalis, which only possess an orphan

225 se antibiotics includes multidrug-resistant (MDR) gram-negative bacteria (GNB), including Pseudomonas

226 Multidrug-resistant (MDR) gram-negative bacteria have increased the prevalenc

227 of infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

228 Multidrug-resistant (MDR) infections are on the increase in health care setti

229 interventions to treat multidrug-resistant (MDR) Pseudomonas aeruginosa infections are severely limi

230 ent smear-positive, and multidrug-resistant (MDR) TB.

231 inadequate treatment of multidrug-resistant (MDR) tuberculosis (i.e., acquired resistance) versus tho

232 r contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published dat

233 es for individuals with multidrug-resistant (MDR) tuberculosis (TB).

234 recent transmission of multidrug-resistant (MDR) tuberculosis and identify potential risk factors fo

235 children fall sick with multidrug-resistant (MDR) tuberculosis every year.

236 se regimen for treating multidrug-resistant (MDR) tuberculosis was recently recommended by the World

237 Multidrug-resistant (MDR) tuberculosis, "Ebola with wings," is a significant

238 s treatment options for multidrug-resistant (MDR) uropathogens are limited, clinicians need to be awa

239 012 muM; SI >/= 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium

240 oprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates, primarily acquired

241 y toxic chemosensitizing agents that reverse MDR effects, which has raised expectations in the develo

242 The ability to reverse MDR of the most active compounds was confirmed in a MTT

243 the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 an

244 nt of clinically useful compounds to reverse MDR.

245 oup), which included monogenic disease risk (MDR) results (associated with Mendelian disorders), carr

246 lofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

247 r the use of these drugs and for the shorter MDR-TB regimen in the pediatric population.

248 By silencing MDR genes in tumors, self-assembled core-shell nanoparti

249 In this study, MDR glioblastoma cell lines were created in response to

250 uberculosis (TB) and multidrug-resistant TB (MDR-TB) are major health problems in Western Province, P

251 berculosis (TB) and multi-drug resistant TB (MDR-TB), repurposing FDA (U.S. Food and Drug Administrat

252 e novo emergence of multi-drug-resistant TB (MDR-TB).

253 results show that SIPI has higher power than MDR (Multifactor Dimensionality Reduction), AA_Full, Gen

254 Multivariable regression showed that MDR (hazard ratio [HR], 5.91 [95% confidence interval {C

255 tly increased potency (~67 fold) against the MDR cancer cells over free DOX.

256 ound 13 showed moderate activity against the MDR Gram-negative strains, with MICs in the range of 16-

257 ICs in the range of 0.5-4 mug/mL against the MDR Staphylococci and Enterococci species.

258 is and treatment is necessary to control the MDR tuberculosis epidemic.

259 with increasing drug-resistance, drives the MDR tuberculosis epidemic in Shanghai, China.

260 with increasing drug-resistance, drives the MDR tuberculosis epidemic in Shanghai, China.

261 that of the mdtK efflux pump (32.14%) in the MDR isolates.

262 Statistical modeling of the MDR ER data demonstrated that an increase in MW as a res

263 ock of the available evidence related to the MDR hypothesis.

264 in MDR-AB rates, greater compliance with the MDR-AB prevention bundle did not lead to reductions in M

265 they were on >/=1 medication to which their MDR-TB strain was likely susceptible.

266 with the synergistic sensitization of those MDR tumor cells to conventional chemotherapeutic agents,

267 The prevalence and mortality attributable to MDR in Thailand are high.

268 ents with hospital-acquired infection due to MDR bacteria in Thailand in 2010 represented excess mort

269 ffectiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness.

270 To address the need for new agents to treat MDR P. aeruginosa, we focused on inhibiting the first co

271 spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR

272 en develop multidrug-resistant tuberculosis (MDR-TB) each year.

273 pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia.

274 Multidrug-resistant tuberculosis (MDR-TB) is an important global public health threat, but

275 Multi-drug-resistant tuberculosis (MDR-TB) is an increasing public health threat, and promp

276 han 30% of multidrug-resistant tuberculosis (MDR-TB) patients are currently diagnosed, due to laborat

277 Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of Mycobacteri

278 ncentrated multidrug-resistant tuberculosis (MDR-tuberculosis) risk in Lima, Peru.

279 better antimicrobial performance against two MDR isolates of Pseudomonas aeruginosa and Acinetobacter

280 Understanding MDR is of fundamental and practical interest to plant bi

281 n the few MDR loci that are well-understood, MDR is conditioned by diverse mechanisms at the locus an

282 itical information about the highly virulent MDR E. coli strain of poultry origin and warrant further

283 cillin nonsusceptible and 16.7% (13/78) were MDR.

284 rsus 9/43 [20.9%] after; P = 0.003) and were MDR.

285 Fifty-three percent of bacteria were MDR, including 95% of Enterococcus faecium and 55% of En

286 The primary outcomes were MDR-GNB acquisition, colonization, and infection; second

287 azid-monoresistant tuberculosis, 25 000 with MDR tuberculosis, and 1200 with XDR tuberculosis.

288 tion, fold-increase of DNR accumulation with MDR inhibition, ease of cell trapping, and ease of maint

289 extensively studied for its association with MDR due to overexpression in cancer cells.

290 ategorization into leukemic blast cells with MDR activity (MDR(+)) and leukemic blast cells without M

291 herapy and relapsed samples, consistent with MDR as a mechanism of relapse in these patients.

292 y between leukemic blasts was observed, with MDR(+) cells not infrequently seen in some patients that

293 the potential to treat cancer patients with MDR in the future.

294 stricting bedaquiline usage to patients with MDR plus additional resistance and withholding bedaquili

295 g bedaquiline available to all patients with MDR TB, restricting bedaquiline usage to patients with M

296 ding bedaquiline access to all patients with MDR TB.

297 235 (73%) patients with MDR tuberculosis probably had transmission of MDR strain

298 successful in treating 71% of patients with MDR-P. aeruginosa infections, most of whom had pneumonia

299 rospective cohort study of 172 subjects with MDR/extensively drug-resistant TB subjects and sequenced

300 ty (MDR(+)) and leukemic blast cells without MDR activity (MDR(-ve)).